Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 29 Mar 2022
Lipocine announces its partner received FDA approval of Tlando
29 March 2022 - Commercial launch expected in 2Q 2022. ...
Posted by Michael Wonder on 29 Mar 2022
Government fails to adequately address medicine affordability for working Australians
29 March 2022 - The cost of medicines will continue to go up unchecked as the Federal Government has failed ...
Posted by Michael Wonder on 29 Mar 2022
Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes
28 March 2022 - Ozempic demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes ...
Posted by Michael Wonder on 29 Mar 2022
Santhera and ReveraGen start rolling NDA submission to the FDA for vamorolone for the treatment of Duchenne muscular dystrophy
29 March 2022 - Santhera Pharmaceuticals and ReveraGen BioPharma announce the initiation of a rolling new drug application submission to the ...
Posted by Michael Wonder on 29 Mar 2022
Consequences of US FDA approval decisions in high-income countries
29 March 2022 - Akhade and colleagues highlight the global consequences of approving cancer medicines on the basis of uncertain evidence ...
Posted by Michael Wonder on 29 Mar 2022
Tarlige tablets approved in Japan for treatment of patients with neuropathic pain
28 March 2022 - Daiichi Sankyo today announced that it has obtained approval in Japan to change the indication of ...
Posted by Michael Wonder on 29 Mar 2022
Budget 2022-23 – no ‘big bang’ announcements in health
29 March 2022 - Medicines Australia welcomes tonight’s Budget announcements for new PBS listings and on-going COVID-19 measures. ...
Posted by Michael Wonder on 29 Mar 2022
Record investment in the future of Australia's health system
29 March 2022 - The Australian Government is investing in a stronger health system as part of our plan for a ...
Posted by Michael Wonder on 29 Mar 2022
Neurocrine Biosciences announces regulatory approval of Dysval (valbenazine) for the treatment of tardive dyskinesia in Japan
29 March 2022 - Neurocrine Biosciences today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation, has obtained regulatory approval of ...
Posted by Michael Wonder on 29 Mar 2022
Ondexxya approved in Japan for reversal of acute major bleeds in patients on factor Xa inhibitors
29 March 2022 - Ondexxya is the first approved reversal agent specifically for factor Xa inhibitors, providing a major advance ...
Posted by Michael Wonder on 29 Mar 2022
European Medicines Agency commences review of novel gene therapy candidate etranacogene dezaparvovec for people with haemophilia B
29 March 2022 - Marketing authorisation application for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to ...
Posted by Michael Wonder on 29 Mar 2022
Seqirus receives Health Canada approval for expanded age indication of its cell-based quadrivalent influenza vaccine for people as young as six months
28 March 2022 - Seqirus announced today that it has received Health Canada approval of Flucelvax Quad (influenza vaccine), its cell-based ...
Posted by Michael Wonder on 28 Mar 2022
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
28 March 2022 - This is the sixth indication for Dupixent in Canada, its second in asthma, and its second in ...
Posted by Michael Wonder on 28 Mar 2022
Te Pāti Māori demand accountability from PHARMAC CE for lie about live saving Trikafta drug cost
28 March 2022 - Today Te Pāti Māori stand in solidarity with the cystic fibrosis community of Aotearoa New Zealand ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...